

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 July 2021 (29.07.2021)



(10) International Publication Number
WO 2021/148983 A1

(51) International Patent Classification:

A61P 7/00 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/IB2021/050464

(22) International Filing Date:

21 January 2021 (21.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/965,688	24 January 2020 (24.01.2020)	US
63/104,213	22 October 2020 (22.10.2020)	US
63/121,467	04 December 2020 (04.12.2020)	US

(71) Applicant: **PFIZER INC.**, [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **APGAR, James Reasoner**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **BOWLEY, Sheryl Rubio**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **ELWELL, Joanne Elizabeth-Ayriss**; c/o Pfizer Inc., 610 Main Street, Cam-

bridge, Massachusetts 02139 (US). **LIN, Laura**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **NARULA, Jatin**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **PARNG, Chuen-iei**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **PITTMAN, Debra Denene**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **RAKHE, Swapnil**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **YU, Chihyi Vincent**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **ZIELINSKI, Bryan C.** et al.; Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: ANTI-E-SELECTIN ANTIBODIES, COMPOSITIONS AND METHODS OF USE




FIG. 7

(57) Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*